NCT00002996

Flecainide in Treating Patients With Chronic Neuropathic Pain

Flecainide for the Treatment of Chronic Neuropathic Pain: A Phase II Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Eastern Cooperative Oncology Group · Network
• Sex: All
• Age: 19 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Flecainide therapy may help patients with neuropathic pain live more comfortably. PURPOSE: Phase II trial to study the effectiveness of flecainide in treating patients with chronic neuropathic pain from cancer or AIDS.

Detailed description

OBJECTIVES: * Investigate the effectiveness of flecainide in the management of neuropathic pain. OUTLINE: Patients are given a brief pain inventory (BPI) form to assess their pain upon enrollment in the study. Following a 7 day stabilization period, flecainide is administered. One capsule of flecainide is given twice a day on days 8-10, two capsules are given twice a day on days 11-14 and three capsules are given twice a day on days 15-21. BPI forms are completed on days 8, 15 and 22 to assess neuropathic pain. PROJECTED ACCRUAL: A total of 7-20 patients will be accrued for this study.

Conditions

• Pain

Interventions

Type	Name	Description
DRUG	flecainide acetate

Timeline

• Start date: 1998-05-04
• Primary completion: 2006-04-01
• First posted: 2003-01-27
• Last updated: 2023-06-15

Locations

6 sites across 1 country: United States